Have you been diagnosed with pancreatic cancer? Please scroll down the page, post a question or comment and I will reply to you ASAP.
“Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing…
These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development…”
“Treatment based on genomic profiling, also known as precision medicine, may hold the promise of improved outcomes for a subset of patients with pancreatic cancer. Pancreatic cancer is the third leading cause of cancer deaths in the United States and with a survival rate of just 8% current treatments are largely ineffective. Genomic profiling, according to a pair of recent studies published by researchers at the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC) may be the key to more effective pancreatic cancer treatment.
The first study investigated genomic changes in 100 patients with gastrointestinal cancer including colorectal and pancreatic cancers. Common mutations in each cancer were identified and recommendations could be made for 38% of patients. However, due to rapid disease progression, only 14% of patients could follow the recommended treatment. Half of the patients following genome-informed therapy treatment showed improved overall survival. One patient had a mutation in the ALK gene, a gene that is commonly implicated in other forms of cancer including breast, colon, and lung for which current drug treatments have been successful.1
The second study investigated the genomic profile of more than 3000 patients with pancreatic cancer. Only 5 patients (0.2%) had mutations in ALK. Four of the 5 patients were treated with commonly used ALK inhibiting drugs. Positive effects including disease stability, tumor shrinkage, and lower levels of a pancreatic specific biomarker were observed in 3 patients.2
“Together, these 2 findings begin to capture the promise of precision medicine in pancreatic cancer, which has so far not experienced the same success with targeted treatments as other cancer types…,”